Sepsis overview and diagnostic market opportunities

The global in vitro diagnostics (IVD) market was valued at $78 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% to reach $104 billion by 2030. Key drivers for this growth include the increasing prevalence of chronic and infectious diseases, as well as the continuous launch of new IVD products by major diagnostics companies (1).

Sepsis, a life-threatening condition caused by a dysregulated immune response to infection, poses a significant global health burden. In the UK alone, approximately a quarter of a million individuals are affected by sepsis annually, resulting in around 50,000 deaths – equivalent to five deaths per hour. Globally, sepsis claims the lives of 11 million people each year (2). In the US, it is the leading cause of hospital deaths, with an annual economic cost of $24 billion (3).

The global sepsis diagnostics market was valued at $840 million in 2023 and is projected to reach nearly $2 billion by 2032, demonstrating a CAGR of 10%.

Key pointers

  • The World Health Organization (WHO,2020) estimated that sepsis globally affects about 50 million people leading to 11 million deaths a year.
  • Increased adoption of rapid diagnostic and point-of-care techniques for early diagnosis is powering market growth
  • The US Centers for Disease Control and Prevention (CDC) claim that around 1 in 3 people who die in a hospital had sepsis during their hospitalisation (August, 2022) (4)

1. In Vitro Diagnostics Market Size, Share, Trends Report 2030

2. About sepsis - The UK Sepsis Trust

3. Global, regional, and national sepsis incidence and mortality, 1990–2017

4. Sepsis Diagnostics Market Size, Share, Analysis Report [2032]